STAMFORD, Conn., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. CARA, a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced that members of its management team will deliver company overviews at three investor conferences in November:
Stifel 2017 Healthcare Conference (New York)
Date: Tuesday, November 14, 2017
Time: 11:00 a.m. ET
Jefferies 2017 London Healthcare Conference (London, UK)
Date: Thursday, November 16, 2017
Time: 4:40 p.m. GMT (11:40 a.m. ET)
29th Annual Piper Jaffray Healthcare Conference (New York)
Date: Tuesday, November 28, 2017
Time: 11:00 a.m. ET
A live audio webcast of each event can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.
About Cara TherapeuticsÂ
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
